Avraham Ashkenazi
banner
ashkenazilab.bsky.social
Avraham Ashkenazi
@ashkenazilab.bsky.social
Investigating the cell biology of proteostasis and misfolded proteins in neurological disorders. Associate Prof. at Tel Aviv University.
https://en-med.m.tau.ac.il/profile/ashkenaziavi
Pinned
Our new paper in @brain1878.bsky.social. 🎉 We identify a new function of #ubiquitin enzyme in #Huntington’s disease models. Great collaboration with the Ellerby Lab.
academic.oup.com/brain/articl...
Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington’s disease
Ishtayeh et al. identify the cancer-associated deubiquitinating enzyme UCHL3 as a potential therapeutic target in Huntington’s disease. Genetic and pharmac
academic.oup.com
Whether extracellular vesicles is the primary source for synuclein section is still under investigation. Now it may be use as a biomarker for Parkinson's disease. Super cool.
February 7, 2026 at 12:25 PM
Reposted by Avraham Ashkenazi
Parkinson’s disease has the fastest-growing prevalence of any neurodegenerative disorder worldwide

go.nature.com/4r0xZsk
Immune cells from the gut drive development of Parkinson’s disease in the brain
In ‘body-first’ Parkinson’s disease, misfolded proteins propagate from the gut’s nervous system to the brain. Immune-cell activity seems to play a key part in this spread.
go.nature.com
February 6, 2026 at 1:24 PM
Reposted by Avraham Ashkenazi
Neurologist Sarah Tabrizi is leading the clinical effort that generate the first gene therapy to treat Huntington’s disease. She’s part of Nature’s 10 for 2025. 🧪
‘Giant step forward’ for Huntington’s — the scientist behind the first gene therapy
Sarah Tabrizi is part of Nature’s 10, a list of people who shaped science in 2025.
go.nature.com
December 31, 2025 at 2:27 PM
Our new paper in @brain1878.bsky.social. 🎉 We identify a new function of #ubiquitin enzyme in #Huntington’s disease models. Great collaboration with the Ellerby Lab.
academic.oup.com/brain/articl...
Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington’s disease
Ishtayeh et al. identify the cancer-associated deubiquitinating enzyme UCHL3 as a potential therapeutic target in Huntington’s disease. Genetic and pharmac
academic.oup.com
February 6, 2026 at 12:13 PM